Niagen acquires QUB NR patent portfolio; $1M upfront, annual payments through 2038

Niagen Bioscience, Inc.

One-time ~$1M payment to QUB for accrued royalties through 2024; annual $500K+£35K through 2038.
Additional one-time payments of $1.5M in 2035 and $2M in 2038 as consideration for patent assignment and release.
QUB assigned all patent rights to ChromaDex; prior JOMA and License Agreement terminated with royalty obligations released.
Acquired portfolio includes composition-of-matter patents for NR salt forms (e.g., NR Malate, NR Tartrate) and global rights.
Niagen now sole owner of core NR IP estate with >90 patents worldwide; CEO cites enhanced control and shareholder protection.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Niagen Bioscience, Inc. entered into Agreement with Queen’s University Belfast valued at approximately $1,000,000 (effective 2025-12-16).

Action: entry
Agreement: asset purchase
Counterparty: Queen’s University Belfast
Value: approximately $1,000,000
Effective: 2025-12-16

Exact text from the filing

On December 18, 2025, ChromaDex, Inc. (the “Company”), a wholly owned subsidiary of Niagen Bioscience, Inc. (the “Registrant”), executed an assignment agreement (the “Agreement”) with Queen’s University Belfast (“QUB”), with an effective date of December 16, 2025.

View on SEC.gov

Browse all material agreements →

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001386570-25-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.